The licensing agreement is expected to close in the first quarter of calendar year 2017. The call will discuss Palatin's role in further development and regulatory approval of Rekynda, and potential licensing transactions outside North America. The call will also discuss Palatin's anticipated next steps in its other drug development programs, including its melanocortin receptor-­1 agonist peptides for treatment of inflammatory and dermatologic disease indications, melanocortin receptor-4 agonist compounds for treatment of obesity and diabetes, and natriuretic peptide receptor-­A agonist compounds for treatment of cardiovascular and pulmonary indications. Palatin will announce the date and time of its conference call and audio webcast shortly after closing of the licensing agreement with AMAG Pharmaceuticals.